BioCentury
ARTICLE | Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Emerging Company Profile: Founded by Guo-Liang Yu and Charlene Liao, the cancer play’s lead is a first-in-class ILT3 inhibitor  

February 26, 2021 11:12 PM UTC

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents.

The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors venture partner who is CEO of cancer company Apollomics Inc., and President and CEO Charlene Liao, who led development of 10 NMEs during a 14-year career at Genentech Inc...

BCIQ Company Profiles

Immune-Onc Therapeutics Inc.